# Title: A *Trypanosoma cruzi* Trans-Sialidase Peptide Demonstrates High Serological Prevalence Among Infected Populations Across Endemic Regions of Latin America

**Authors:** Hannah M. Kortbawi[1,2]†, Ryan J. Marczak[3,4]†, Jayant V. Rajan[1]‡, Nash L. Bulaong[5], John E. Pak[5], Wesley Wu[5], Grace Wang[5], Anthea Mitchell[5], Aditi Saxena[5]§, Aditi Maheshwari[3,4]‖, Charles J. Fleischmann[4]¶, Emily A. Kelly[4], Evan Teal[4], Rebecca L. Townsend[6], Susan L. Stramer[6]††, Emi E. Okamoto[7]#, Jacqueline E. Sherbuk[7]**, Eva H. Clark[8,9], Robert H. Gilman[10], Rony Colanzi[11], Efstathios D. Gennatas[3,12], Caryn Bern[3]*, Joseph L. DeRisi[1,5]*, Jeffrey D. Whitman[4]*

**Affiliations:**

[1]Department of Biochemistry and Biophysics, University of California San Francisco; San Francisco, CA, USA.

[2]Medical Scientist Training Program, University of California San Francisco; San Francisco, CA, USA.

[3]Department of Epidemiology and Biostatistics, University of California San Francisco; San Francisco, CA, USA.

[4]Department of Laboratory Medicine, University of California, San Francisco; San Francisco, CA, USA.

[5]Chan Zuckerberg Biohub San Francisco; San Francisco, CA, USA.

[6]Scientific Affairs, American Red Cross; Gaithersburg, MD, USA.

[7]New York University School of Medicine; New York, NY, USA.

[8]Section of Infectious Diseases, Department of Medicine, Baylor College of Medicine; Houston, TX, USA.

[9]Division of Tropical Medicine, Department of Pediatrics, Baylor College of Medicine; Houston, TX, USA.

[10]Johns Hopkins University Bloomberg School of Public Health; Baltimore, MD, USA.

[11]Universidad Catolica Boliviana; Santa Cruz, Plurinational State of Bolivia.

[12]Department of Medicine, University of California San Francisco; San Francisco, CA, USA.

†, Authors contributed equally.

‡, JVR current affiliation, Current affiliation Pfizer, Inc; Collegeville, PA, USA.

§, AS current affiliation, Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health; Boston, MA, USA.

‖, AM current affiliation, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

¶, CJF current affiliation, Noorda College of Osteopathic Medicine; Provo, UT, USA.

#, EEO current affiliation, Independent Consultant.

**, JES current affiliation, University of South Florida; Tampa, FL, USA.

††, SLS current affiliation, Infectious Disease Consultant, North Potomac, MD

*, Corresponding authors, caryn.bern2@ucsf.edu, joe@derisilab.ucsf.edu,
jeffrey.whitman@ucsf.edu.

**One Sentence Summary:** Phage display immunoprecipitation sequencing (PhIP-seq) designed
with a *T. cruzi* whole proteome library reveals a trans-sialidase peptide antigen (TS-2.23) with
antibody responses highly prevalent across endemic regions of Latin America.

**Abstract:** Infection by *Trypanosoma cruzi*, the agent of Chagas disease, can irreparably damage
the cardiac and gastrointestinal systems during decades of parasite persistence and related
inflammation in these tissues. Diagnosis of chronic disease requires confirmation by multiple
serological assays due to the imperfect performance of existing clinical tests. Current serology
tests utilize antigens discovered over three decades ago with small specimen sets predominantly
from South America, and lower test performance has been observed in patients who acquired *T.
cruzi* infection in Central America and Mexico. Here, we attempt to address this gap by
evaluating antibody responses against the entire *T. cruzi* proteome with phage display
immunoprecipitation sequencing comprised of 228,127 47-amino acid peptides. We utilized
diverse specimen sets from Mexico, Central America and South America, as well as different
stages of cardiac disease severity, from 185 cases and 143 controls. We identified over 1,300
antigenic *T. cruzi* peptides derived from 961 proteins between specimen sets. A total of 67
peptides were reactive in 70% of samples across all regions, and 3 peptide epitopes were
enriched in ≥90% of seropositive samples. Of these three, only one antigen, belonging to the
trans-sialidase family, has not previously been described as a diagnostic target. Orthogonal
validation of this peptide demonstrated increased antibody reactivity for infections originating
from Central America. Overall, this study provides proteome-wide identification of seroreactive
*T. cruzi* peptides across a large cohort spanning multiple endemic areas and identified a novel
trans-sialidase peptide antigen (TS-2.23) with significant potential for translation into diagnostic
serological assays.

**Main Text:**

**INTRODUCTION**

Chagas disease is caused by infection with the protozoan parasite, *Trypanosoma cruzi*, which is
transmitted by triatomine insect vectors. The disease is endemic to the Americas, with vector-
borne transmission occurring in suitable ecological zones of Latin America (*1*). In the United
States (US), the major disease burden occurs among Latin American immigrant populations
exposed in their birth countries, although rare autochthonous infections have been documented in
Texas, California, Arizona, Tennessee, Mississippi and other southern states (*2, 3*). Chronic
Chagas disease is considered a lifelong infection without treatment. *T. cruzi* can infect many
nucleated cell types but causes pathology in the cardiac and gastrointestinal systems. An
estimated 20 to 30% of people with chronic Chagas disease develop symptoms of end organ
damage after years to decades of infection. Related cardiac presentations include cardiac
conduction system deficits, dilated cardiomyopathy, and sudden cardiac death (*4*). Ten percent of
infected individuals may develop gastrointestinal dysmotility disorders (*5, 6*). Because this
parasite is predominantly intracellular in the chronic phase and symptoms are largely non-

existent or non-specific, detection of anti-*T. cruzi* antibodies in peripheral blood is the most
sensitive method for diagnosis and is the only reliable means of screening asymptomatic patients.

The test performance of current Chagas disease serology assays does not have the accuracy
(sensitivity or specificity) to effectively diagnose patients by one test alone (*7*). Pan American
Health Organization/World Health Organization (PAHO/WHO) guidelines require confirmation
by two tests with distinct antigen sources. The indications for *T. cruzi* serology span many areas
of healthcare, including clinical diagnosis, blood donor screening, and solid organ or
hematopoietic stem cell transplant donor and recipient testing (*8-11*). In practice, securing repeat
testing for patients and identifying clinical laboratories that offer more than one serology test can
be difficult and time consuming, and ultimately patients may be lost to follow-up. Given the
mounting awareness of the need for Chagas disease screening and imperfect test performance, it
is clear that the serology assays themselves must be improved to increase the effectiveness of
screening and diagnosis efforts.

Recent studies evaluating regionally-diverse Chagas disease populations highlight differential
reactivity to commercial *T. cruzi* serology assays between infected populations; with the lowest
reactivity in individuals from Mexico, intermediate reactivity from Central America, and the
highest reactivity from South America (*12-15*). Up to an estimated 10% loss in sensitivity
between infections originating from Mexico compared to South America has been observed
depending on the assay used (*12*). Other studies based in endemic areas have documented
decreased performance of commercial serological assays in regions of Mexico and Central
America, as well as Peru (*16-19*). *T. cruzi* is a genetically diverse parasite, currently classified
into six genetic lineages or discrete typing units (DTUs: TcI – TcVI) (*20*), plus a potential
seventh, bat-associated genotype (TcBat), most closely related to TcI (*21*). It is hypothesized that
host immunological responses and antigenic differences between regional *T. cruzi* strains may be
the basis of the differential serological responses. However, the areas with problematically low
reactivity to commercial assays are largely found where TcI is predominant, but not all TcI-
predominant areas show low reactivity (*22*). Genetic variation is also high within TcI (*23*),
suggesting that DTU-level classification is not sufficiently granular to map host immunology to
parasite genetics.

The antigens used in current commercial diagnostics originated from a surge of Chagas disease
serology research over the last three decades (*24*). These studies tended to rely on screening with
sera from high prevalence regions of South America, where TcII/V/VI are predominant; mainly
Brazil and Argentina. Since then, more robust techniques for antigen discovery have emerged in
the form of high-density peptide microarrays. Recent application of these techniques to Chagas
disease have generated additional antigen targets (*25-27*). However, these studies used pooled
sera for determining the initial down selection of antigenic targets for secondary peptide array
libraries. Such an approach is unable to discern commonality of antigens across the entire *T.*
*cruzi* proteome among the pooled sera. The antigen targets chosen for follow-on validation in
individual specimens were therefore biased towards the highest reactivity antigens within a pool,
not necessarily the highest prevalence antigens.

To address these gaps, we employed phage display immunoprecipitation sequencing (PhIP-seq)
(*28*) using a synthetic oligonucleotide library with high-density coverage of the *T. cruzi*
proteome using 47 amino acid peptides. We performed immunoprecipitation using 185 serology-
confirmed cases from geographically diverse regions of Latin America to explicitly represent the
genetic diversity of *T. cruzi* antigens across DTUs, as well as varying presentations of Chagas

cardiomyopathy to control for any differences by disease severity. The goal of this study was to
employ a next-generation antigen discovery technique to *T. cruzi* and evaluate high-prevalence
antigen targets with translational potential for serological diagnostics.

## RESULTS

### Development of *T. cruzi* proteome library

130 We constructed a T7 phage-display library to display the entire *T. cruzi* CL Brener proteome in
131 49-amino acid (aa) peptides with a 19-mer overlap in consecutive sequences (*Materials and*
132 *Methods*, Fig. 1). The library includes 228,127 *T. cruzi* peptides that represent 19,607 proteins.
133 Over 99.6% of the ordered peptides were represented in the final cloned library, with 90% of
134 peptides represented within a 9-fold difference of read counts (Fig. S1).

135
**Fig. 1. PhIP-seq library design and assay steps.** Phage library displays the proteome of *T.*
*cruzi* in 47-aa peptides with a 19-aa step size on the capsid of T7 phage. The library
includes all coding regions of the proteome and splice variants. We performed the PhIP-
seq assay by incubating the phage library with human plasma, followed by
immunoprecipitation of antibodies in the sample and enrichment of antibody-bound
phage through lysis in *E. coli*. We performed two rounds of enrichment and then
sequenced the enriched phage to obtain the identity of the immunoprecipitated peptides.

### PhIP-seq identifies antibodies to *T. cruzi* peptides

We performed PhIP-seq on peripheral blood samples from three distinct specimen sets including
US blood donors with routine Chagas disease serology screening (BD, *n*=90; *n*=64 seropositive,
*n*=26 seronegative), a Chagas disease cardiac biomarker study (CBM, *n*=143; *n*=121
seropositive, *n*=22 seronegative), and independent healthy controls (NYBC, *n=95*). See
*Materials and Methods* for a full description of these specimens. The PhIP-seq library contained
human GFAP sequences, so a polyclonal anti-GFAP antibody was used as a positive control for
immunoprecipitation. Positive control samples were highly enriched for GFAP peptides (Fig.
S2). We excluded ten samples from the analysis due to low sequencing read counts; seven
seropositive CBM samples, two seronegative CBM study samples, and one NYBC control. In
total, 185 cases and 143 controls were included for further data analysis.

We used a conservative analysis approach to identify antibody reactivity to individual *T. cruzi*
peptides that were enriched (z-score ≥5) in at least 5% of seropositive patients (Fig. S3). Z-
scores were calculated based on the distribution of sequencing reads per 100,000 (RPK) value
for a given peptide in seronegative patients, which included endemic region seronegative
controls as well as independent seronegative controls from the US. With this approach, 5,638
individual peptides representing 4,001 proteins were enriched in the seropositive CBM samples,
and 8,710 peptides representing 5,629 proteins were enriched in the seropositive BD samples.

Between both cohorts, 12,978 antigenic peptides corresponding to 7,373 unique proteins were
identified, with an overlap of 1,370 peptides across 961 proteins in both Chagas disease study
sets (Fig. S4). A total of 67 and 85 peptides were reactive in at least 70% of samples among the
BD samples and CBM samples, respectively. Across both cohorts, 43 of these 70% seroreactivity
peptides were shared.

**Significantly enriched *T. cruzi* antigens in seropositive samples**

The antigenic peptides identified across both specimen sets represented 38% of the 19,607-
member proteome of *T. cruzi*. Most of these peptides demonstrated no enrichment in
seronegative samples (Fig. 2a, b). The median number of enriched Chagas disease-specific
peptides in each seropositive sample was higher in the BD specimens compared to the CBM
specimens (Fig. 2c), but the mean number of enriched peptides per sample did not significantly
differ within cohorts by patient region of origin (BD specimens) or by heart disease stage (CBM
specimens) (Kruskall-Wallis, BD $H(2) = 1.77$, $p = 0.41$; CBM $H(3) = 2.49$, $p = 0.48$).

The proteins from which the enriched peptides derive are predominantly expressed in the host
phase lifecycle stages of *T. cruzi* (metacyclic trypomastigotes, trypomastigotes, and amastigotes)
(*29*) (Fig. 2d). There were relatively fewer seroreactive peptides that corresponded to proteins
expressed in the epimastigote form, which only occurs in the gut of the triatomine vector.
Examples of host phase-specific proteins that had high antibody reactivity included trans-
sialidases and mucin-associated surface proteins.

**Fig. 2. PhIP-seq captures known antigens across the *T. cruzi* life cycle stages. (A,B)** Heatmap of z-score enrichment over seronegative controls in the (A) blood donor (BD) specimens (n=64 seropositive, n=26 seronegative) and the (B) cardiac biomarker (CBM) specimens (n=114, seropositive; n=18, seronegative; n=95, healthy controls) for seroreactive peptides (rows) with >15% seropositivity within each cohort. Peptides are sorted by protein name and samples are sorted by patient region of origin (n=10, Central America [yellow]; n=13, Mexico [blue]; n=12, South America [light green]; n=1, USA [pink]; n=28, unknown [green]) (A), or cardiac disease stage (n=14 stage A seronegative [magenta]; n=6 stage B seronegative [orange]; n=38 stage A seropositive [magenta]; n=46 stage B seropositive [orange]; n=7 stage C seropositive [light green]; n=23 stage D seropositive [blue]) (B). Protein groups with well-characterized antigens are indicated by labels (Surface antigen, Surface antigen 2 (CA-2); NSP-like, Nucleoporin NSP1-like C-

terminal domain-containing protein; MASP, Mucin-associated surface protein; Mucin,
TcMUCII; MAP, Microtubule-associated protein; CCP, Calpain-like cysteine peptidase;
60S, 40S, ribosomal subunit proteins). (**C**) Breadth of antibody reactivity, shown as the
number of seroreactive peptides in each person. The dotted red line and number signify
the median number of seroreactive peptides in BD and CBM specimen sets. Samples are
grouped by geographic region (BD specimens) and heart disease stage (CBM specimens).
(**D**) Number of peptides identified as seroreactive in this study that are part of proteins
expressed in specific stages of the *T. cruzi* life cycle (Tryp = trypomastigote; Ama =
amastigote; Meta = metacyclic trypomastigote; Epi = epimastigote; Multiple = protein is
expressed in trypomastigote, amastigote, and/or metacyclic trypomastigote stages). Stage
expression analysis shows seroreactive peptides in every host-interfacing lifecycle stage.
Stage-specific expression is based on the 'Life cycle proteome (Brazil)' data set from
TriTrypDB. Gene IDs for stage-specific proteins were mapped onto the gene IDs that
corresponded to seroreactive peptides. (**E**,**F**) Selected known seroreactive antigens are
captured by *T. cruzi* PhIP-seq. Neg. is seronegative specimens from the respective
specimen sets; Pos. is seropositive specimens from the respective cohorts; NYBC is
NYBC US controls. Antibody reactivity to two known antigens (E) Ag2, a nucleoporin
protein, and (F) TCE, a 60S ribosomal subunit protein are plotted as reads per 100,000
(RPK). The dotted red line signifies the RPK that corresponds to a z-score cutoff of 5 in
the seronegative population of each cohort.

**Identification of high-prevalence *T. cruzi* antigens across Latin America**

To identify high-prevalence antigens shared across endemic regions representing different *T.*
*cruzi* DTUs, we first analyzed BD specimens, which included individuals born in Mexico,
Central America and South America. We performed two complementary approaches to identify
individual antigens with sufficient seroprevalence to have utility for clinical diagnostic assays.
First, we used the z-scored, peptide-level data to identify peptides enriched in ≥90% of
seropositive BD samples. Second, we used mass univariate analysis to create a ranked list of top
antigenic peptides by largest predictor coefficient values. The mass univariate analysis approach
models peptide RPK scores based on diagnostic status in our BD specimens. All peptides
identified by the z-score approach were also identified as significantly enriched by the mass
univariate analysis (Fig. S5). These analyses were then performed on the CBM specimens to
evaluate for any differences in high-prevalence antigens by cardiac disease status; none were
identified.

These analyses yielded 23 peptides (Table S1), including 20 peptides that all contain the
repetitive PFGQAAAGDKPS antigenic sequence, present in a current diagnostic antigen known
as Ag 2 (*30, 31*) (Fig. 2e). An additional highly reactive peptide, which contained the antigenic
sequence KAAAPKKAAAPQ, has high sequence homology to another known diagnostic
antigen, TcE (*32*) (Fig. 2f). The final two high-prevalence peptides belonged to the trans-
sialidase family (Fig. 3a) and shared the sequence
APGETK[V/I]PSELNATIPSDHDILLEFR[D/E]LAAMALIG. To our knowledge, this peptide is
novel as a diagnostic antigen candidate.

**Epitope mapping and validation of the high-prevalence trans-sialidase antigen**

To orthogonally validate antibody reactivity to the high-prevalence trans-sialidase peptide, we
performed a split-luciferase binding assay (SLBA). Briefly, we generated the trans-sialidase

peptide with a C-terminal HiBiT tag and immunoprecipitated it with plasma from 4 seropositive
BD patient samples with the highest PhIP-seq RPK values and five independent healthy US
controls. Incubation of the immunoprecipitated peptides with LgBiT produces luminescence as a
quantitative measurement of antibody binding. Four Chagas disease seropositive samples with
high PhIP-seq enrichment were reactive to the trans-sialidase peptide, while seronegative control
samples were not (Fig. 3b).

A sequential alanine-scan was performed to further map the reactive epitope of the trans-
sialidase peptide. Using samples from 5 seropositive BD patients, we determined that the critical
region for immunoreactivity was a ten aa sequence that spans positions 648 to 658 of the full-
length trans-sialidase protein (DILLEFRELA) (Fig. 3c). To be permissive of the epitope we
chose a final antigenic sequence of IPSDHDILLEFRELA, corresponding to the two alanine
blocks with the lowest reactivity, henceforth be referred to as TS-2.23. Basic local alignment
search tool (BLAST) analysis of TS-2.23 in NCBI database identified 37 proteins from all *T.
cruzi* entries with >93% (15-aa) sequence identity, all of which were from trans-sialidase or
putative trans-sialidase genes.

252
**Fig. 3. A novel trans-sialidase peptide sequence is a highly reactive serological antigen.** (**A**)
Anti-trans-sialidase peptide antibody reactivity is plotted as RPK. The dotted red line
signifies the RPK that corresponds to a z-score cutoff of 5 in the seronegative population
of each cohort. (**B**) Trans-sialidase reactivity orthogonal validation using a split-
luciferase binding assay (SLBA). Reactivity was tested against four seropositive blood
donor specimens and five seronegative US healthy control specimens. (**C**) Alanine-
scanning mutagenesis in 10-aa windows (highlighted in red) across the entire trans-
sialidase antigenic fragment demonstrates the seroreactive epitope in Chagas disease.

Values are normalized antibody indices and represent the averages of five seropositive
blood donor specimens.

**Evaluation of trans-sialidase antigen TS-2.23 antibody reactivity**

To evaluate the potential of TS-2.23 as a diagnostic serology antigen, we compared its PhIP-seq
performance to that of current diagnostic antigens. To address the fact that current diagnostic
antigen sequences vary at certain amino acids from available sequencing data (*33*) and the
specific antigen sequences used in commercial diagnostics are not publicly available for all
assay, we agnostically derived the aa sequence motifs of eight diagnostic antigens used in US
Food and Drug Administration (FDA)-cleared serology tests (*24*) using Multiple EM for Motif
Elicitation (MEME) (see *Materials and Methods*) (Fig. S6) (*34-36*). These motifs were then
queried against the entire *T. cruzi* PhIP-seq proteome using FIMO to identify all peptides with a
significantly similar sequence to each antigen (*37*). The maximum z-score for each BD sample
across all PhIP-seq peptides with a sequence match to a given antigen motif was plotted (Fig.
4a). The maximum z-score across all peptides with a sequence match to TS-2.23 was also shown
to compare the novel antigen reactivity to those in used in current diagnostics. Any sample with
a z-score of at least 5 for a peptide that contained an antigen motif was considered enriched for
antibody reactivity prevalence calculations (Fig. 4b). TS-2.23 had high prevalence, demonstrated
in 100% (64/64) of the seropositive BD samples and 95% (108/114) of CBM seropositive
samples. By comparison, only Ag 2 and TcE had similar antibody reactivity and prevalence
across seropositive specimens. In contrast, Ag 1, Ag13 and Ag36 had similar prevalence but
lower reactivity, and KMP-11 was rarely enriched.

| Antigen | BD Prevalence (*n* = 64) | CBM Prevalence (*n* = 114) |
|---------|--------------------------|----------------------------|
| Ag2 | 98% | 97% |
| TcE | 98% | 95% |
| Ag1 | 95% | 98% |
| SAPA | 95% | 93% |
| Ag13 | 94% | 82% |
| Ag36 | 89% | 96% |
| Ag30 | 47% | 77% |
| KMP-11 | 6% | 12% |
| TS-2.23 | 100% | 95% |

**Fig. 4. PhIP-seq antibody reactivity of current diagnostic antigens and TS-2.23 within individual Chagas disease seropositive specimens.** Recombinant antigens in current FDA-cleared serology tests include Ag 1, Ag 2, Ag 13, Ag 30, Ag 36 (33, 34), shed acute phase antigen (SAPA) (35), KMP-11 (36), TcD and TcE (30, 37). Note, TcD contains the same antigenic epitope as Ag 13. (**A**) Heatmap of z-score enrichment over seronegative controls in the seropositive blood donor (BD) specimens (n=64). Each antigen motif was derived using Multiple EM for Motif Elicitation (MEME) and then scored against the entire *T. cruzi* PhIP-seq proteome. The maximum z-score across all peptides with significant sequence matches to a given antigen motif was plotted for each sample and each antigen. (**B**) Percent of samples enriched ( z-score ≥5) for each antigen in BD and cardiac biomarker (CBM) specimen sets.

To further validate and directly characterize the antibody reactivity of TS-2.23, we performed a
quantitative IgG biolayer interferometry (BLI) immunoassay on 336 BD specimens with
previous Chagas disease serology testing (n=250, seropositive; n=86, seronegative) (*Materials
and Methods*, Fig. 5a). Seropositive samples were chosen to include all specimens with region of
origin data (Mexico, n=92; Central America, n=86; South America, n=72) (Fig. 5b). The results
of the pairwise comparisons between regions demonstrated seroreactivity was lower in
individuals from Mexico compared to Central America (*p*<0.0001) and South America (*p*=
0.00021). Specimens from individuals from Central America and South America did not show
differences in reactivity (*p*=1.000). Seronegative specimens did not demonstrate any overt non-
specific reactivity to the TS-2.23 antigen.

**Fig. 5. Biolayer interferometry validates trans-sialidase antigen TS-2.23 seroreactivity in a**
**large cohort.** (**A**) Schematic of biolayer interferometry (BLI) approach. BLI uses a
fiberoptic probe to measure the wavelength of light reflected from the surface of a
biosensor, which changes due to light interference when an analyte binds. First, an anti-
His tag probe is incubated with His-tagged antigen. Then, the probe is incubated in
diluted serum or plasma, and antibodies bind the immobilized antigen on the probe. To
quantify IgG-specific reactivity, anti-IgG antibodies are added and bind the immobilized
patient antibodies. (**B**) Seropositive blood donor specimens (n = 250) demonstrate a range
of reactivity to the trans-sialidase antigen by quantitative BLI immunoassay, while
seronegative blood donor specimens (n=86) do not (Wilcoxon rank-sum test). Reactivity,
as denoted by wavelength shift, was higher in Central American (n=86) and South
American (n=72) specimens than in Mexican specimens (n=92). Dashed line
corresponds to the 25th percentile across all seropositive specimens.

To evaluate if specimens with low reactivity to TS-2.23 are weakly reactive overall, we
compared TS-2.23 reactivity with previous results from an FDA-cleared Chagas disease serology
ELISA (Chagatest Recombinante v.3.0, Wiener Labs [Wv3]). This assay contains a multi-
epitope recombinant antigen comprised of Ag 1, Ag 2, Ag 13, Ag 30, Ag 36, and SAPA (*30, 31*).
Analysis of the 25th percentile of TS-2.23 BLI reactivity yielded 63 specimens originally positive

by blood donor testing.  The reactivity (signal-to-cutoff ratio) of the Wv3 ELISA was in the 25th
percentile of previous testing (*12*) for 70% (44/63) of the low reactive TS-2.23 BLI specimens.
This comparison to previous Wv3 ELISA test results suggests that most low reactivity TS-2.23
specimens are weakly reactive specimens overall. Breakdown of these specimens by region of
origin included 60% (38/63) from Mexico, 24% (15/63) from Central America, and 16% (10/63)
from South America.

**DISCUSSION**

Chagas disease is a neglected tropical disease endemic to the Americas, affecting over 6 million
people worldwide (*1*). Numerous diagnostic challenges for chronic Chagas disease exist,
including low clinical awareness, non-specific or asymptomatic presentation, and imperfect test
performance (*38, 39*). In addition to better testing for populations with epidemiological risk
factors for exposure to triatomine vectors, effective testing is needed for at-risk people presenting
for prenatal screening, blood donation and organ transplant evaluation (*8-11*). The major
disparities for Chagas disease serology testing are insufficient sensitivity and specificity of any
one diagnostic test to be used alone and differential serological test performance by region of
origin of *T. cruzi* infection.

To address this, we carried out our *T. cruzi* PhIP-seq study in two well-characterized Chagas
disease specimen sets, which represent the largest number of samples evaluated for *T. cruzi*
antigen discovery, to our knowledge. One set (BD) includes specimens from individuals born in
Mexico, Central America and South America, collected via blood donation in the US (*12*). An
additional set (CBM) includes Bolivians with varying stages of Chagas cardiomyopathy,
collected via a clinical study of cardiac biomarkers (*40*). Analysis of these two specimen sets by
PhIP-seq identified more than 1,300 reactive *T. cruzi* peptides highly specific to individuals with
Chagas disease. Down selection on common antigens amongst Chagas disease seropositive
individuals filtered to only three antigenic sequences with sufficient prevalence for diagnostic
utility (enrichment in ≥90% of specimens). This vast difference between total reactive peptides
and high-prevalence antigens illustrates the uniqueness of the adaptive immune system response
within an individual host. By contrast, the rare high-prevalence antigens warrant further research
into the host-pathogen biology that drives their immunodominance.

Two of these high-prevalence antigens were identified by multiple groups from early phage
display studies and are already incorporated into current serological diagnostics: Ag 2 (*30, 31*), a
nucleoporin protein, and TcE (*41*), a 60S ribosomal subunit protein. The third and, in fact, most
prevalent peptide antigen discovered in our study, TS-2.23, has not previously been described as
a serological diagnostic antigen and belongs to the trans-sialidase family. Trans-sialidase
enzymes comprise a unique pathogenic and antigenic family of secreted and
glycophosphatidylinositol (GPI)-anchored cell surface proteins in *T. cruzi*. Their primary
functional activity is to transfer sialic acids from mammalian cells to beta-galactosidase residues
on *T. cruzi's* cell membrane to assist in cell invasion (*42*). Trans-sialidases also appear to
modulate the host immune response, likely acting as decoy antigens (*43*). The evidence for this
relates to the discovery of the shed acute phase antigen (SAPA), a multi-repeat antigen located at
the C-terminal end of trans-sialidase enzymes (*44*). Since the catalytic end is in the N-terminal
region, it is hypothesized that C-terminal antigens evolved to protect the trans-sialidase enzyme
activity from humoral responses. BLAST analysis of the trans-sialidase antigen identified by our
study showed 37 *T. cruzi* proteins with >93% sequence identity, all of which were trans-sialidase

or putative trans-sialidase genes. All sequences were located at C-terminal end, matching with
the immunodominant nature of known antigens from this family.

Our findings also demonstrate that the TS-2.23 antigen identified in this study has increased
antibody reactivity in specimens from individuals born in Central America, compared to
previous analyses of the same specimens by current clinical diagnostics (*12*). Beyond the
potential implications for endemic populations in Central America, identification of TS-2.23 is
important for screening and diagnosis in the US considering that a large proportion of the Latin
American immigrant population is predominantly from El Salvador and Guatemala. Further
studies evaluating Central American Chagas disease populations with a combination of
conventional antigens and TS-2.23 will be needed to identify real-world increases in diagnostic
test performance. While this is a promising advancement, unfortunately, TS-2.23 does not have
improved seroreactivity in individuals who acquired *T. cruzi* infection in Mexico. Further study
is needed to evaluate whether this is due to lower anti-*T. cruzi* IgG levels in individuals exposed
in Mexico or the absence of regional *T. cruzi* antigens of Mexican origin. Post-translational
protein glycosylation may be a source of unique antigenicity outside of the primary peptide
sequence (*45*).

Our study is limited by retrospective selection bias on samples tested by current diagnostic
assays. Prospective testing in at-risk populations will be important to further validate the TS-2.23
antigen. We do not report on the sensitivity or specificity of the TS-2.23 antigen in comparison
to previous testing because these assays contain between 6 to 9 different antigens in a
multiepitope format. The evaluation of test performance by TS-2.23 should be done in
combination with these recombinant multiepitope assays to generate test performance
characteristics, which are planned for follow-on studies. Ultimately, to create the ideal serologic
test for diagnosis of chronic Chagas disease, we would combine the fewest recombinant targets
for a multiepitope antigen that approaches 100% sensitivity and specificity to eliminate the need
for confirmatory testing for all initial *T. cruzi* seropositive results. Such a test would greatly
facilitate Chagas disease screening, diagnosis, and treatment.

In summary, our study has discovered a novel *T. cruzi* trans-sialidase peptide antigen (TS-2.23)
that is serologically reactive and prevalent across endemic countries of Latin America and
varying degrees of cardiac disease severity. Future studies will evaluate the real-world test
performance in traditional immunoassay formats common in clinical laboratories.

**MATERIALS AND METHODS**

**Study Design**

Samples used in this study included blood donor plasma collected within the US and serum from
clinical research collected in Bolivia. The blood donor plasma samples were provided in
collaboration with the American Red Cross (ARC) with sample selection criteria described
previously (*12*). All blood donor specimens (BD) were confirmed by blood donor testing assays
and algorithms (*9*). A subset of specimens was used for antigen discovery experiments (n=90;
n=64, seropositive; n=26, seronegative). Region of origin data was available for 35 specimens
(n=13, Mexico; n=10, Central America; n=12, South America). The serum samples from clinical
research studies in Bolivia were collected as part of a cardiac biomarker (CBM) study (*40*).
Specimens were collected from a large public hospital in Santa Cruz, tested and confirmed for *T.*
*cruzi* serostatus and further stratified for cardiac status by clinical assessment, electrocardiogram
and echocardiography studies. In total, 143 serum samples were included for this study,

including 22 seronegative (n=15, without significant cardiac abnormalities [Stage A]; n=7, with
cardiac abnormalities [Stage B]) and 121 seropositive (n=40, without significant cardiac
abnormalities [Stage A]; n= 81, with cardiac abnormalities[Stages B-D]). Cardiac staging is
defined as: A, normal electrocardiogram (ECG), normal echocardiography (echo); B, abnormal
ECG, normal echo; C, 40-55% ejection fraction (EF) by echo, normal left ventricular end
diastolic diameter (LVEDD); D, EF<40% or LVEDD >57mm. Specimens were randomized to
96-well plates prior to testing and frozen at -20˚C. A separate set of *T. cruzi* seronegative plasma
specimens (n=95) from the New York Blood Center (NYBC) was used as an independent
negative control for antigen discovery experiments with the CBM specimen set.

Institutional review board for research use of de-identified human biospecimens was approved
by the University of California San Francisco. The BD study protocol was approved by
institutional review board at the American Red Cross. The CBM study protocol was approved by
the Institutional Review Boards of Universidad Catolica Boliviana (Santa Cruz, Bolivia) and
included consent for future use of deidentified specimens (*40*). NYBC specimens consisted of
de-identified plasma obtained from adults who donated blood to the New York Blood Center.

**Construction of *T. cruzi* phage library**

Reference protein sequences for the *T. cruzi* strain CL Brener assembly GCF_000209065.1 (*46*)
were obtained from the National Center of Biotechnology Information (NCBI) site. All
sequences in the peptidome were processed using a previously described bioinformatic pipeline
(*47*). Briefly, all full-length protein sequences were decomposed into a series of overlapping
peptides. Each peptide was 47 amino acids in length with consecutive peptides overlapping by
19 amino acids. The full set of peptides was collapsed using the command line tool cd-hit (*48,*
*49*) at 90% sequence similarity, resulting in a final set of 228,127 peptides spanning the *T. cruzi*
peptidome (19,607 proteins). Peptides tiling over the length of the glial fibrillary acidic protein
(GFAP) were added to the library as a positive control for immunoprecipitation. Peptide
sequences were converted to their coding DNA sequences with common 5'
(GTAGCTGGTGTTGTAGCTGCC) and 3' (GGTGACTACAAGGATGATGATGATAAA)
linker sequences appended to each peptide encoding sequence. The 3' linker sequence encoded a
FLAG tag). The final library, consisting of 228,162 peptides that correspond to 19,608 proteins,
was ordered from Agilent Technologies.

**Cloning and packaging into T7 phage**

The oligo pool was received in a single tube, lyophilized, and was resuspended to 0.2 nM. The
pool was amplified using Phusion polymerase (New England Biolabs [NEB]) and linker-specific
primers (TAGTTAAGCGGAATTCAGTAGCTGGTGTTGTAGCTGCC,
ATCCTGAGCTAAGCTTTTTATCATCATCATCCTTGTAGTCACC). The amplified library
was purified using Ampure XP magnetic beads (Beckman Coulter) and confirmed to have a
single-size product by gel electrophoresis. One µg of the cleaned library was then digested using
EcoRI-HF and HindIII-HF restriction enzymes (NEB) and purified again using Ampure XP
beads. Digestion of the library product was confirmed by visualizing a 20bp size shift using the
Bioanalyzer High Sensitivity DNA Analysis kit (Agilent). The digested library was cloned into
T7 Select vector arms (Novagen 70550-3) as previously described (*47*). Four packaging
reactions were performed and then pooled. The final phage library was grown up in BLT5403 *E.*
*coli* (Novagen 70550-3).

**Immunoprecipitation of antibody-bound phage**

PhIP-seq was performed using the *T. cruzi* peptide phage display library with plasma or serum
samples using our previously-published PhIP-seq protocol (https://www.protocols.io/view/derisi-
lab-phage-immunoprecipitation-sequencing-ph-4r3l229qxl1y/v1). Patient plasma was diluted 1:1
in storage buffer (0.04% NaN3, 40% Glycerol, 40 mM HEPES (pH 7.3), 1 x PBS (-Ca and –
Mg)) to preserve antibody integrity. One uL of diluted plasma was incubated with 500 µL of the
input phage display library for the first round of immunoprecipitation. Positive control
immunoprecipitations were performed using 1 µL of 1:10 diluted anti-GFAP antibody (Dako,
Z0334) (Figure S2). Ten µL of Dynabeads Protein A/G slurry (ThermoFisher Scientific) were
used per sample. After one round of immunoprecipitation, phage were amplified in *E. coli* and
enriched in a second round of immunoprecipitation. The final lysate was spun and stored at 4 °C
for NGS library prep. Immunoprecipitated phage lysate was heated to 70 °C for 15 min to expose
DNA. DNA was then prepared for next-generation sequencing in two subsequent PCR
amplifications. The final prepared libraries were sequenced using an Illumina sequencer to a read
depth of approximately 1 million reads per sample.

**PhIP-seq data analysis**

Sequencing reads from fastq files were aligned to the reference *T. cruzi* peptide library and
individual peptide counts were normalized to reads per 100,000 (RPK) by dividing by the sum of
counts and multiplying by 100,000 to account for varying read depth. All subsequent analyses
were performed using Python (version 3.12.2) unless otherwise noted.

To identify Chagas disease-specific enriched peptides and avoid false positives, a conservative
analysis pipeline was used as follows. Peptide-level enrichment across known seronegative
samples was calculated and used to generate z-scores ((x-mean seronegative)/standard deviation
seronegative) for the Chagas disease seropositive, seronegative, and NYBC control samples. The
z-score for any seronegative sample was calculated by leaving out that sample from the mean of
seronegative samples for each peptide. A moving threshold analysis was implemented to
determine the z-score threshold and the number of Chagas disease patients that must share
enrichment to a given peptide to completely differentiate seropositive and seronegative patients
(Figure S3). Based on this analysis, z-score cutoff of 5 and shared enrichment across at least five
percent of Chagas disease samples (n≥3 BD specimens; n≥ 5 CBM specimens) and one or fewer
seronegative samples was set for hit calling.

Additional validation of the z-score approach was executed using a mass univariate analysis
using generalized linear models applied to each peptide. Peptide fragments with uniform values
across all samples were removed due to lack of variability. RPK values were scaled by
subtracting the mean and dividing by the standard deviation calculated within each peptide.
Scaled RPK values for each peptide were regressed on Chagas disease diagnostic status ($y_i = \beta_{0i}$
$+ \beta_{1i} \cdot x$) where $y_i$ is the scaled RPK value, $\beta_{0i}$ is the intercept of the *i*-th peptide fragment, $\beta_{1i}$ is
the predictor coefficient, and *x* is the diagnostic status in BD samples or cardiac disease stage in
CBM samples. The resulting coefficient quantified the strength and direction of the association
between diagnostic status (or disease stage) and the scaled RPK values for each peptide, where
positive coefficient values represent, on average, a higher RPK for that peptide in seropositive
specimens. Analyses were performed using R (version 4.3.1).

Antigenic prevalence of a *T. cruzi* peptide was calculated as the number of seropositive samples
enriched for a specific peptide divided by the number of seropositive samples in the respective

specimen set (BD and CBM). High-prevalence antigens were designated as enrichment in ≥90%
of seropositive specimens and no seronegative specimens.

**Split Luciferase Binding Assay (SLBA)**

A high-prevalence antigen by PhIP-seq that was not already included in commercial diagnostics
was selected for orthogonal validation by SLBA. A detailed SLBA protocol can be found online
at https://www.protocols.io/view/split-luciferase-binding-assay-slba-protocol-4r3l27b9pg1y/v1.
Briefly, the high-prevalence peptide antigen was inserted into a split luciferase construct
containing a T7 promoter and a terminal HiBiT tag and synthesized as DNA oligomers (Twist
Biosciences). The oligos were amplified using 5′-
AAGCAGAGCTCGTTTAGTGAACCGTCAGA-3′ and 5′-
GGCCGGCCGTTTAAACGCTGATCTT-3′ primer pair and purified using the DNA Clean and
Concentrator-5 kit (Zymo). Purified PCR products were transcribed and translated *in vitro*
(IVTT) using wheat germ extract (Promega L4140) and the Nano-Glo HiBiT Lytic Detection
System (Promega, N3040) was used to quantify translated protein using relative luciferase units
(RLU) detected on a luminometer. Background luminescence was calculated using an IVTT
reaction that used a construct encoding a STOP codon 5' of the HiBiT tag. Peptides were
normalized to $2 \times 10^7$ RLU per well, incubated overnight with patient plasma or a positive
control anti-HiBiT antibody (Promega, N7200), and immunoprecipitated with a Dynabeads
Protein A/G bead slurry. The immunoprecipitation was washed four times with SLBA buffer
(0.15 M NaCl, 0.02 M Tris-HCl pH 7.4, 1% w/v sodium azide, 1% w/v bovine serum albumin,
and 0.15% v/v Tween 20) and remaining luminescence was measured using the Nano-Glo HiBiT
Lytic Detection System in a luminometer. Antibody index was calculated as (RLU sample –
RLU mock IP)/(RLU sample – RLU anti-HiBiT) for orthogonal validation of the trans-sialidase
peptides. For epitope mapping by alanine-scanning mutagenesis, the antibody index was
calculated as (RLU seropositive – RLU US control)/(RLU seropositive – RLU anti-HiBiT) and
normalized to the antibody index of immunoprecipitation using the wild-type peptide sequence.

**MEME and FIMO Motif Analysis**

To empirically re-derive a selected diagnostic antigen motif, all BD-enriched peptides were
filtered to those peptides that mapped to the antigenic protein (e.g., any enriched peptide that
belonged to a nucleoporin protein for Ag2). These peptide sequences were queried using *MEME*
(MEME 5.5.7) with the following *meme* command options and parameters:

-protein -mod zoops -nmotifs 10 -minw 6 -maxw 15 -objfun classic -markov_order 0

The derived motifs were then manually inspected to identify the motif that clearly matched the
published diagnostic antigen sequences (Figure S6) (*24*). This motif (or multiple motifs, if the
antigen sequence was over 47 amino acids, as in the case of Ag1 and Ag36) was then queried
against the entire *T. cruzi* PhIP-seq proteome using the following *fimo* command options and
parameters:

--thresh 1e-4 --qv-thresh

The only exceptions to this analysis were antigens Ag13, TcE, and KMP-11. Ag13 and TcE are
short, highly repetitive antigens, and so were identified using the *meme* parameter -mod anr. The
final antigenic motif identified for TcE was very short (6 amino acids) and thus required
different *fimo* significance thresholds to identify similar sequences. A q-value threshold of 1e-2
was set for this antigen only. Finally, KMP-11 was represented by only three overlapping

peptides that map to kinetoplastid membrane protein KMP-11 (XP_808865.1), so motif
discovery was not possible. To look for sequence similarity across the *T. cruzi* proteome, the 92-
amino acid KMP-11 protein was queried against the proteome using *blastp* (BLAST 2.12.0) and
no other peptides with significant sequence similarity were identified. The three KMP-11
peptides alone were used for downstream analysis of KMP-11 antigen reactivity.

To assess the reactivity of patient samples against these antigen motifs, the maximum z-score
across all peptides with a sequence match to a given antigen motif was plotted for each BD
sample.

**Peptide Antigen Expression**

We selected a minimal antigenic peptide sequence that consisted of the 15-aa that, when mutated
via alanine scanning, produced the lowest binding signal on SLBA (Figure 3c), to test using
biolayer interferometry (BLI). This peptide sequence was repeated seven times in series to create
a final protein that was approximately 13 kDa. The insert sequence was synthesized by Twist
Bioscience in a pET-21(+) vector, with a C-terminal 6X His tag and under control of a T7
promoter and lac repressor.

The expression plasmid was transformed into BL21(DE3) competent *E. coli* (Thermo
Scientific) and plated onto Luria-Bertani (LB) agar plates containing carbenicillin. Isolates were
expanded in 1L LB broth with carbenicillin grown at 37°C to an OD600 of 0.6. The culture was
induced with 1mM Isopropyl β-D-1-thiogalactopyranoside and grown at 25°C shaking for
another 18 hours. The cells were then centrifuged at 10,000 RPM for 30 minutes at 4°C to collect
the cell pellet.

A stock lysis buffer (20 mM sodium phosphate, 20 mM imidazole, 500 mM NaCl, 0.5 mM
TCEP, 5% glycerol, pH 7.4) was made with EDTA-free (Roche) per 50 mL. The pelleted cells
were resuspended in 100mL of cold lysis buffer and run through a LM10 microfluidizer at
15,000 PSI for 5 cycles. The flowthrough lysate was collected after each cycle and combined.
The lysate was centrifuged at 12,500 RPM for 30 minutes at 4°C. The supernatant was collected
and filtered through a 0.22 µm vacuum filtration device.

Recombinant His-tagged antigen was purified from the filtered lysate using a Ni-NTA resin
gravity flow column. After loading the lysate to the column, the column was washed with a wash
buffer (20 mM sodium phosphate, 40 mM imidazole, 500 mM NaCl, 0.5 mM TCEP, pH 7.4).
The antigen was eluted with an elution buffer (20 mM sodium phosphate, 500 mM imidazole,
500 mM NaCl, 0.5 mM TCEP, pH 7.4). Peptide yield from the purification was quantified using
NanoDrop (Thermo Scientific), and the purity of the product was verified by protein gel
electrophoresis. Expression of the peptide was confirmed by anti-His tag Western blot using a
6X-His tag monoclonal antibody (Invitrogen, MA1-21315).

**Biolayer Interferometry (BLI) Serological Immunoassay**

A GatorPrime analyzer (Gator Bio) was used to perform BLI to evaluate the antibody reactivity
to the recombinant peptide antigen. BLI uses a fiberoptic probe to measure the wavelength of
light (nanometers [nm]) reflected from the surface of a biosensor, which shifts in response to
analyte binding (Figure 5a). Quantitative BLI serological immunoassay can be performed by
measuring nm shift to antigen-bound probe incubated in diluted serum or plasma and
subsequently in anti-human immunoglobulin (IgG) for quantifying class-specific responses. BLI
methodology was chosen for these analyses because it has a higher dynamic range for assessing

antibody-antigen reactivity compared to traditional colorimetric enzyme-linked immunosorbent
assays (ELISA) (*50*). An anti-*T. cruzi* IgG BLI method was developed using a commercial *T.*
*cruzi* Chimeric Chagas Multi-Antigen (MACH; Jena Biosciences). This is a polypeptide chain of
87-aas with epitopes from previously known antigens: Peptide 2, TcD, TcE, and SAPA, fused
with a 6His-Tag. This BLI method was optimized using high, intermediate, and low reactivity
seropositive BD specimens previously determined by Chagatest Recombinante v.3.0 anti-T.cruzi
ELISA (Wiener Labs), which contain the MACH antigens.

The anti-*T.cruzi* IgG BLI assay was adapted for the recombinant antigen discovered by PhIP-seq
by varying the protein concentration to achieve saturation of nm shift signal of the anti-His tag
fiberoptic probe (Figure S7). The final method consisted of the following BLI conditions: 1) 600
second (s) incubation of anti-His probe in 2ug/mL peptide antigen, 2) 1800s incubation in 10uL
of plasma diluted 1:19 with Q-Buffer diluent (GatorBio), and 3) 2000s incubation in a solution of
10ug/mL goat anti-human IgG (Jackson Immunoresearch). Steps 1 and 2 were followed by a
360s wash in Q-Buffer. Endpoint nm shift measurements were normalized by subtracting the nm
shift value after antigen loading wash (step 1) to account for any minor variation in the amount
of immobilized antigen.

Anti-*T. cruzi* IgG BLI was performed on 336 BD specimens (n = 250, seropositive; n=86,
seronegative) to evaluate antibody reactivity to the peptide antigen. Region of origin data was
available for all seropositive specimens (Mexico, n=92; Central America, n=86; South America,
n=72). Wilcoxon rank sum analysis with a correction for multiple comparisons using the
Bonferroni method was completed to compare reactivity between regions.

**Statistical analysis**

Associations between number of individual antibody targets and heart disease stage or region of
infection were tested using Kruskal-Wallis tests. Motif analysis was performed using MEME and
FIMO (*34-36*). Associations between anti-TS-2.23 BLI reactivity, serologic status, and region
were tested using the Wilcoxon rank-sum test with a correction for multiple comparisons using
the Bonferroni method.

**List of Supplementary Materials**

Fig. S1 to S7

Table S1

**References and Notes**

1.    S. World Health Organization = Organisation mondiale de la, Chagas disease in Latin
America : an epidemiological update based on 2010 estimates = Maladie de Chagas en
Amérique latine : le point épidémiologique basé sur les estimations de 2010. *Weekly*
*Epidemiological Record = Relevé épidémiologique hebdomadaire* **90**, 33-44 (2015).
2.    A. Irish, J. D. Whitman, E. H. Clark, R. Marcus, C. Bern, Updated Estimates and
Mapping for Prevalence of Chagas Disease among Adults, United States. *Emerg Infect*
*Dis* **28**, 1313-1320 (2022).
3.    C. Bern, L. A. Messenger, J. D. Whitman, J. H. Maguire, Chagas Disease in the United
States: a Public Health Approach. *Clin Microbiol Rev* **33**, (2019).

4.    M. C. P. Nunes, A. Beaton, H. Acquatella, C. Bern, A. F. Bolger, L. E. Echeverria, W. O.
Dutra, J. Gascon, C. A. Morillo, J. Oliveira-Filho, A. L. P. Ribeiro, J. A. Marin-Neto, E.
American Heart Association Rheumatic Fever, Y. Kawasaki Disease Committee of the
Council on Cardiovascular Disease in the, C. Council on, N. Stroke, C. Stroke, Chagas
Cardiomyopathy: An Update of Current Clinical Knowledge and Management: A
Scientific Statement From the American Heart Association. *Circulation* **138**, e169-e209
(2018).
5.    A. Perez-Ayala, J. A. Perez-Molina, F. Norman, B. Monge-Maillo, M. V. Faro, R. Lopez-
Velez, Gastro-intestinal Chagas disease in migrants to Spain: prevalence and methods for
early diagnosis. *Ann Trop Med Parasitol* **105**, 25-29 (2011).
6.    R. B. de Oliveira, L. E. Troncon, R. O. Dantas, U. G. Menghelli, Gastrointestinal
manifestations of Chagas' disease. *Am J Gastroenterol* **93**, 884-889 (1998).
7.    Pan American Health Organization. (2019), vol. 2021.
8.    C. J. Forsyth, J. Manne-Goehler, C. Bern, J. Whitman, N. S. Hochberg, M. Edwards, R.
Marcus, N. L. Beatty, Y. E. Castro-Sesquen, C. Coyle, P. Stigler Granados, D. Hamer, J.
H. Maguire, R. H. Gilman, S. Meymandi, Recommendations for Screening and Diagnosis
of Chagas Disease in the United States. *J Infect Dis* **225**, 1601-1610 (2022).
9.    R. Y. Dodd, J. A. Groves, R. L. Townsend, E. P. Notari, G. A. Foster, B. Custer, M. P.
Busch, S. L. Stramer, Impact of one-time testing for Trypanosoma cruzi antibodies
among blood donors in the United States. *Transfusion* **59**, 1016-1023 (2019).
10.    O. P. T. N. . (2023), vol. 2023.
11.    P. V. Chin-Hong, B. S. Schwartz, C. Bern, S. P. Montgomery, S. Kontak, B. Kubak, M. I.
Morris, M. Nowicki, C. Wright, M. G. Ison, Screening and treatment of chagas disease in
organ transplant recipients in the United States: recommendations from the chagas in
transplant working group. *Am J Transplant* **11**, 672-680 (2011).
12.    J. D. Whitman, C. A. Bulman, E. L. Gunderson, A. M. Irish, R. L. Townsend, S. L.
Stramer, J. A. Sakanari, C. Bern, Chagas Disease Serological Test Performance in U.S.
Blood Donor Specimens. *J Clin Microbiol* **57**, (2019).
13.    Y. E. Castro-Sesquen, A. Saldana, D. Patino Nava, T. Bayangos, D. Paulette Evans, K.
DeToy, A. Trevino, R. Marcus, C. Bern, R. H. Gilman, K. R. Talaat, P. Chagas Working
Group in, S. the United, Use of a Latent Class Analysis in the Diagnosis of Chronic
Chagas Disease in the Washington Metropolitan Area. *Clin Infect Dis* **72**, e303-e310
(2021).
14.    C. Truyens, E. Dumonteil, J. Alger, M. L. Cafferata, A. Ciganda, L. Gibbons, C. Herrera,
S. Sosa-Estani, P. Buekens, Geographic Variations in Test Reactivity for the Serological
Diagnosis of Trypanosoma cruzi Infection. *J Clin Microbiol* **59**, e0106221 (2021).
15.    E. A. Kelly, C. A. Bulman, E. L. Gunderson, A. M. Irish, R. L. Townsend, J. A. Sakanari,
S. L. Stramer, C. Bern, J. D. Whitman, Comparative Performance of Latest-Generation
and FDA-Cleared Serology Tests for the Diagnosis of Chagas Disease. *J Clin Microbiol*,
(2021).
16.    J. R. Verani, A. Seitz, R. H. Gilman, C. LaFuente, G. Galdos-Cardenas, V. Kawai, E. de
LaFuente, L. Ferrufino, N. M. Bowman, V. Pinedo-Cancino, M. Z. Levy, F. Steurer, C.
W. Todd, L. V. Kirchhoff, L. Cabrera, M. Verastegui, C. Bern, Geographic variation in
the sensitivity of recombinant antigen-based rapid tests for chronic Trypanosoma cruzi
infection. *Am J Trop Med Hyg* **80**, 410-415 (2009).

17. D. Guzman-Gomez, A. Lopez-Monteon, M. de la Soledad Lagunes-Castro, C. Alvarez-
Martinez, M. J. Hernandez-Lutzon, E. Dumonteil, A. Ramos-Ligonio, Highly discordant
serology against Trypanosoma cruzi in central Veracruz, Mexico: role of the antigen used
for diagnostic. *Parasit Vectors* **8**, 466 (2015).
18. E. Z. Caballero, R. Correa, M. S. Nascimento, A. Villarreal, A. Llanes, N. Kesper, Jr.,
High sensitivity and reproducibility of in-house ELISAs using different genotypes of
Trypanosoma cruzi. *Parasite Immunol* **41**, e12627 (2019).
19. R. Gamboa-Leon, C. Gonzalez-Ramirez, N. Padilla-Raygoza, S. Sosa-Estani, A. Caamal-
Kantun, P. Buekens, E. Dumonteil, Do commercial serologic tests for Trypanosoma cruzi
infection detect Mexican strains in women and newborns? *J Parasitol* **97**, 338-343
(2011).
20. B. Zingales, M. A. Miles, D. A. Campbell, M. Tibayrenc, A. M. Macedo, M. M. Teixeira,
A. G. Schijman, M. S. Llewellyn, E. Lages-Silva, C. R. Machado, S. G. Andrade, N. R.
Sturm, The revised Trypanosoma cruzi subspecific nomenclature: rationale,
epidemiological relevance and research applications. *Infect Genet Evol* **12**, 240-253
(2012).
21. A. Marcili, L. Lima, M. Cavazzana, A. C. Junqueira, H. H. Veludo, F. Maia Da Silva, M.
Campaner, F. Paiva, V. L. Nunes, M. M. Teixeira, A new genotype of Trypanosoma
cruzi associated with bats evidenced by phylogenetic analyses using SSU rDNA,
cytochrome b and Histone H2B genes and genotyping based on ITS1 rDNA.
*Parasitology* **136**, 641-655 (2009).
22. K. A. Alroy, C. Huang, R. H. Gilman, V. R. Quispe-Machaca, M. A. Marks, J. Ancca-
Juarez, M. Hillyard, M. Verastegui, G. Sanchez, L. Cabrera, E. Vidal, E. M. Billig, V. A.
Cama, C. Naquira, C. Bern, M. Z. Levy, P. Working Group on Chagas Disease in,
Prevalence and Transmission of Trypanosoma cruzi in People of Rural Communities of
the High Jungle of Northern Peru. *PLoS Negl Trop Dis* **9**, e0003779 (2015).
23. J. D. Ramirez, C. Hernandez, Trypanosoma cruzi I: Towards the need of genetic
subdivision?, Part II. *Acta Trop* **184**, 53-58 (2018).
24. T. Bhattacharyya, N. Murphy, M. A. Miles, Diversity of Chagas disease diagnostic
antigens: Successes and limitations. *PLOS Neglected Tropical Diseases* **18**, e0012512
(2024).
25. G. Cooley, R. D. Etheridge, C. Boehlke, B. Bundy, D. B. Weatherly, T. Minning, M.
Haney, M. Postan, S. Laucella, R. L. Tarleton, High throughput selection of effective
serodiagnostics for Trypanosoma cruzi infection. *PLoS Negl Trop Dis* **2**, e316 (2008).
26. A. D. Ricci, L. Bracco, E. Salas-Sarduy, J. M. Ramsey, M. S. Nolan, M. K. Lynn, J.
Altcheh, G. E. Ballering, F. Torrico, N. Kesper, J. C. Villar, I. S. Marcipar, J. D. Marco,
F. Aguero, The Trypanosoma cruzi Antigen and Epitope Atlas: antibody specificities in
Chagas disease patients across the Americas. *Nat Commun* **14**, 1850 (2023).
27. A. Majeau, E. Dumonteil, C. Herrera, Identification of highly conserved Trypanosoma
cruzi antigens for the development of a universal serological diagnostic assay. *Emerg*
*Microbes Infect* **13**, 2315964 (2024).
28. D. Mohan, D. L. Wansley, B. M. Sie, M. S. Noon, A. N. Baer, U. Laserson, H. B.
Larman, PhIP-Seq characterization of serum antibodies using oligonucleotide-encoded
peptidomes. *Nat Protoc* **13**, 1958-1978 (2018).

29. J. A. Atwood, 3rd, D. B. Weatherly, T. A. Minning, B. Bundy, C. Cavola, F. R. Opperdoes, R. Orlando, R. L. Tarleton, The Trypanosoma cruzi proteome. *Science* **309**, 473-476 (2005).

30. C. F. Ibanez, J. L. Affranchino, A. C. Frasch, Antigenic determinants of Trypanosoma cruzi defined by cloning of parasite DNA. *Mol Biochem Parasitol* **25**, 175-184 (1987).

31. C. F. Ibanez, J. L. Affranchino, R. A. Macina, M. B. Reyes, S. Leguizamon, M. E. Camargo, L. Aslund, U. Pettersson, A. C. Frasch, Multiple Trypanosoma cruzi antigens containing tandemly repeated amino acid sequence motifs. *Mol Biochem Parasitol* **30**, 27-33 (1988).

32. R. L. Houghton, D. R. Benson, L. D. Reynolds, P. D. McNeill, P. R. Sleath, M. J. Lodes, Y. A. Skeiky, D. A. Leiby, R. Badaro, S. G. Reed, A multi-epitope synthetic peptide and recombinant protein for the detection of antibodies to Trypanosoma cruzi in radioimmunoprecipitation-confirmed and consensus-positive sera. *J Infect Dis* **179**, 1226-1234 (1999).

33. A. Majeau, L. Murphy, C. Herrera, E. Dumonteil, Assessing Trypanosoma cruzi Parasite Diversity through Comparative Genomics: Implications for Disease Epidemiology and Diagnostics. *Pathogens* **10**, (2021).

34. R. L. Houghton, Y. Y. Stevens, K. Hjerrild, J. Guderian, M. Okamoto, M. Kabir, S. G. Reed, D. A. Leiby, W. J. Morrow, M. Lorca, S. Raychaudhuri, Lateral flow immunoassay for diagnosis of Trypanosoma cruzi infection with high correlation to the radioimmunoprecipitation assay. *Clin Vaccine Immunol* **16**, 515-520 (2009).

35. Wiener Lab Group. (2004), vol. 2020.

36. T. L. Bailey, C. Elkan, Fitting a mixture model by expectation maximization to discover motifs in biopolymers. *Proc Int Conf Intell Syst Mol Biol* **2**, 28-36 (1994).

37. C. E. Grant, T. L. Bailey, W. S. Noble, FIMO: scanning for occurrences of a given motif. *Bioinformatics* **27**, 1017-1018 (2011).

38. K. K. Stimpert, S. P. Montgomery, Physician awareness of Chagas disease, USA. *Emerg Infect Dis* **16**, 871-872 (2010).

39. E. A. Kelly, J. I. Echeverri Alegre, K. Promer, J. Hayon, R. Iordanov, K. Rangwalla, J. J. Zhang, Z. Fang, C. Huang, C. E. Bittencourt, S. Reed, R. M. Andrade, C. Bern, E. H. Clark, J. D. Whitman, Chagas Disease Diagnostic Practices at Four Major Hospital Systems in California and Texas. *J Infect Dis* **229**, 198-202 (2024).

40. E. E. Okamoto, J. E. Sherbuk, E. H. Clark, M. A. Marks, O. Gandarilla, G. Galdos-Cardenas, A. Vasquez-Villar, J. Choi, T. C. Crawford, R. Q. Do, A. B. Fernandez, R. Colanzi, J. L. Flores-Franco, R. H. Gilman, C. Bern, B. Chagas Disease Working Group in, Peru, Biomarkers in Trypanosoma cruzi-infected and uninfected individuals with varying severity of cardiomyopathy in Santa Cruz, Bolivia. *PLoS Negl Trop Dis* **8**, e3227 (2014).

41. D. F. Hoft, K. S. Kim, K. Otsu, D. R. Moser, W. J. Yost, J. H. Blumin, J. E. Donelson, L. V. Kirchhoff, Trypanosoma cruzi expresses diverse repetitive protein antigens. *Infect Immun* **57**, 1959-1967 (1989).

42. C. A. Buscaglia, O. Campetella, M. S. Leguizamon, A. C. Frasch, The repetitive domain of Trypanosoma cruzi trans-sialidase enhances the immune response against the catalytic domain. *J Infect Dis* **177**, 431-436 (1998).

43. A. F. Nardy, C. G. Freire-de-Lima, A. R. Perez, A. Morrot, Role of Trypanosoma cruzi Trans-sialidase on the Escape from Host Immune Surveillance. *Front Microbiol* **7**, 348 (2016).

44. J. L. Affranchino, C. F. Ibanez, A. O. Luquetti, A. Rassi, M. B. Reyes, R. A. Macina, L. Aslund, U. Pettersson, A. C. Frasch, Identification of a Trypanosoma cruzi antigen that is shed during the acute phase of Chagas' disease. *Mol Biochem Parasitol* **34**, 221-228 (1989).

45. N. Murphy, B. Rooney, T. Bhattacharyya, O. Triana-Chavez, A. Krueger, S. M. Haslam, V. O'Rourke, M. Panczuk, J. Tsang, J. Bickford-Smith, R. H. Gilman, K. Tetteh, C. Drakeley, C. M. Smales, M. A. Miles, Glycosylation of Trypanosoma cruzi TcI antigen reveals recognition by chagasic sera. *Sci Rep* **10**, 16395 (2020).

46. N. M. El-Sayed, P. J. Myler, D. C. Bartholomeu, D. Nilsson, G. Aggarwal, A. N. Tran, E. Ghedin, E. A. Worthey, A. L. Delcher, G. Blandin, S. J. Westenberger, E. Caler, G. C. Cerqueira, C. Branche, B. Haas, A. Anupama, E. Arner, L. Aslund, P. Attipoe, E. Bontempi, F. Bringaud, P. Burton, E. Cadag, D. A. Campbell, M. Carrington, J. Crabtree, H. Darban, J. F. da Silveira, P. de Jong, K. Edwards, P. T. Englund, G. Fazelina, T. Feldblyum, M. Ferella, A. C. Frasch, K. Gull, D. Horn, L. Hou, Y. Huang, E. Kindlund, M. Klingbeil, S. Kluge, H. Koo, D. Lacerda, M. J. Levin, H. Lorenzi, T. Louie, C. R. Machado, R. McCulloch, A. McKenna, Y. Mizuno, J. C. Mottram, S. Nelson, S. Ochaya, K. Osoegawa, G. Pai, M. Parsons, M. Pentony, U. Pettersson, M. Pop, J. L. Ramirez, J. Rinta, L. Robertson, S. L. Salzberg, D. O. Sanchez, A. Seyler, R. Sharma, J. Shetty, A. J. Simpson, E. Sisk, M. T. Tammi, R. Tarleton, S. Teixeira, S. Van Aken, C. Vogt, P. N. Ward, B. Wickstead, J. Wortman, O. White, C. M. Fraser, K. D. Stuart, B. Andersson, The genome sequence of Trypanosoma cruzi, etiologic agent of Chagas disease. *Science* **309**, 409-415 (2005).

47. J. V. Rajan, M. McCracken, C. Mandel-Brehm, G. Gromowski, S. Pollett, R. Jarman, J. L. DeRisi, Phage display demonstrates durable differences in serological profile by route of inoculation in primary infections of non-human primates with Dengue Virus 1. *Sci Rep* **11**, 10823 (2021).

48. W. Li, A. Godzik, Cd-hit: a fast program for clustering and comparing large sets of protein or nucleotide sequences. *Bioinformatics* **22**, 1658-1659 (2006).

49. L. Fu, B. Niu, Z. Zhu, S. Wu, W. Li, CD-HIT: accelerated for clustering the next-generation sequencing data. *Bioinformatics* **28**, 3150-3152 (2012).

50. M. Dysinger, L. E. King, Practical quantitative and kinetic applications of bio-layer interferometry for toxicokinetic analysis of a monoclonal antibody therapeutic. *J Immunol Methods* **379**, 30-41 (2012).

**Acknowledgments:** We thank members of the DeRisi Lab for helpful discussions during these studies. We also acknowledge the New York Blood Center for contribution of healthy control plasma. Contents herein are the sole responsibility of the authors and do not necessarily represent the official views of the NIH or other funding agencies.

**Funding:**

Chan Zuckerberg Biohub (JLD)

Chan Zuckerberg Biohub Physician-Scientist Fellowship Program (JDW)

**Author contributions:**

Conceptualization: JLD, JDW, CB, JVR

Methodology: JDW, JLD, CB, JVR, HMK, RJM, EDG, NLB, JJP, WW, RLT, SLS,
EEO, JES, EHC, RHG, RC

Investigation: HMK, RJM, JDW, JVR, AM, NLB, GW, AM, AS, CJF, EAK, ET

Formal analysis: HMK, RJM, JVR

Visualization: HMK, RJM, JDW, JVR

Funding acquisition: JLD, JDW

Project administration: JDW, JLD

Supervision: JDW, JLD, CB, EDG

Writing – original draft: JDW, HMK, RJM

Writing – review & editing: All co-authors

**Competing interests:** JDW is a medical consultant for MelioLabs Inc. RJM is an employee of
Agilent Technologies. HMK, RJM, JDW, CB, JVR, and JLD are inventors on a
provisional patent application by the Regents of the University of California and the
Chan Zuckerberg Biohub San Francisco that covers peptide antigens related to TS-2.23.
The other authors declare that they have no competing interests.

**Data and materials availability:** All raw and processed data will be available for download on
Dryad. PhIP-seq analytical code will be available at https://github.com/hkortbawi.